Introduction

MYH9-related disorders (MYH9-
and sometimes hearing loss and cataract) [1, 2] . The bleeding tendency is mild to moderate and easy bruising, epistaxis and menorrhagia are the most prevalent symptoms [3] .
Despite thrombocytopenia, episodes of thrombosis have been reported in a minor subset of patients [3, 4] . In one systematic review seven patients with thrombotic events are described, four with myocardial infarctions, one with stroke and two with venous thrombosis (recurrent deep venous thrombosis and portal venous thrombosis respectively) [4] . Another review described two members of the same family with MYH9-RD who developed coronary artery disease and myocardial infarction requiring coronary artery bypass surgery [3] .
No particular MYH9 mutation has been associated with an increased risk of thrombosis and it has been speculated that the increased platelet volume could to some extent compensate for thrombocytopenia and cause thrombosis in patients with a high risk profile [5] .
Thrombin generation (TGA) and thrombelastography are assays testing the global coagulation capacity, which has been applied in hemophilia patients [6, 7] , patients at risk for thrombosis [8, 9] , as well as in the transfusion setting [10] . We found higher values of TGA parameters in MHY9-RD patients who developed thrombosis compared to MYH9-RD patients without thrombosis.
Methods
Patient population
Patients referred to the Coagulation Unit, Skane University Hospital, Malmö with MYH9-RD were asked to participate in the study. Six patients belonging to two different families (A and B) agreed. With informed consent blood samples were drawn (citrated blood as well as EDTA) with atraumatic technique.
Bleeding score
The bleeding tendency was assessed by the BAT/ISTH score [11] . A value <4 was considered normal.
Routine analyses
Hemoglobin (Hgb), white cell blood count (WBC), platelet count and mean platelet volume (MPV) were measured on an automated cell counter (Sysmex XN-10,Sysmex, Osaka japan).
Since automated cell counters sometime have difficulties to distinguish enlarged platelets from red blood cells and thus, might underestimate platelet counts, platelets counts were also determined manually on a blood smear. In case of divergent results, results from the manual count were used. Antithrombin, protein C, protein S, FV Leiden mutation, prothrombin mutation, lupus anticoagulant, and homocysteine were determined by routine procedures at the Department of Clinical Chemistry, Skane University Hospital, Malmö. Born platelet aggregation was performed on a Chrono-Log-aggregometer, Triolab, Mölndal Sweden using ADP, epinephrine, collagen, ristocetin and arachidonic as agonists.
Genetic analyses
Genomic DNA was isolated from peripheral blood using standard techniques. 
Light microscopy and immunoflourescence
Blood smears were either stained by May-Grünwald-Giemsa stain to assess platelets and granulocytes and by immunofluorescence using a polyclonal rabbit anti-non-muscular myosin IIA (Sigma-Aldrich Chemie GmbH, Steinheim, Germany).
Rotational thrombelastography (ROTEM)
ROTEM analyses were performed on a ROTEM Delta (Triolab, Mölndal, Sweden), according to the instructions of the manufacturer and using EXTEM and INTEM as starting agents. Clotting time (CT), angle, clot formation time (CFT) and maximum clot firmness (MCF) were recorded.
Thrombin Generation
Preparation of platelet rich and platelet poor plasma
Blood samples were collected into tubes containing 0.129 m citrate. "Platelet rich plasma" (PRP) was prepared by centrifuging the tubes once for 10 min at 200 g. Platelet poor plasma (PPP) was prepared by centrifuging the tubes repeatedly two times for 20 min at 1830g. Platelet count should be adjusted to 150 by measuring the platelet count in a cell counter (Coulter Ac T diff 2, Beckham Coulter) and dilution with PPP. However, due to the low platelet count of all included patients, the platelet count could not be adjusted and was below 50 in all patients. PRP was then frozen at 80ºC and thawed for 10 minutes at 37ºC just before the assay.
Thrombin generation assay, CAT
Thrombin generation assay (CAT) was carried out using calibrated automated thrombin generation method (CAT) on frozen/thawed PRP and PPP. 
Plasma exchange experiment
PPPof the two members with arterial thrombosis (A1 and A3) was added to PRP of a healthy donor and diluted with PPP from the patients to obtain a final concentration of 40x10 9 platelets/mL; the same platelet count as was present in the PRP of these two patients thereafter peak thrombin and ETP were determined. Addition of normal PPP to the same platelets served as control.
Results and Discussion
Patient characteristics
In family A, four members were evaluated: a 51 year old woman (platelet count 36; A1), the brother of A1 (57 years; platelet count 39; A2), the 24 year old daughter of A1 (platelet count and A3) had a moderate bleeding tendency (ISTH /SSC bleeding scores 9, 13, 4). In A1 and A2, renal insufficiency and hearing loss were already present. A1 had a myocardial infarction and A2 a pons infarction before the age of 50 and both were treated for hyperlipidemia. The present laboratory evaluation revealed mild hyperhomocysteinemia in both siblings, all other thrombophilia markers were normal.
In family B, macrothrombocytopenia and small to medium size inclusion bodies of NMMHCIIA were found in the leucocytes of the 38-year old proposita (platelet count 36; B1) and her 15-year old daughter (platelet count 46; B2). Platelet aggregation studies showed loss of the shape change after stimulation with collagen in both mother and daughter. The underlying mutation in the MYH9 gene c.4679T>G resulted in the amino acid change p.(Val1560Gly). Thrombophilia testing was normal in both members of the family and bleeding tendency was mild (bleeding scores 4 and 3 respectively).
Results from Global Coagulation tests
Thrombelastography (ROTEM) was normal in all six individuals of the two families, while thrombin generation showed interesting differences. Peak thrombin concentration in PPP was elevated in all four members of the family A while it was normal in family B. The ETP in PPP was normal in both families. In PRP, ETP was found to be below the normal range in family B, which should be expected since the platelet count was just one third of that of control PRP. However, in family A, the two members affected by thrombosis had a normal ETP despite the low platelet count (Fig 2) . Since ETP in PRP reflects both the contribution of coagulation factors as well as the contribution of platelets to thrombin generation, these findings could be explained either by an increased availability of platelet phospholipids, due to the larger size of the platelets, or by a plasma factor present in the patients that presented with thrombosis. To address this question, plasma from these two patients was added to platelets of normal donors. With the plasma of both patients, the ETP (+7±4%) and peak thrombin concentration (+13.6± 1.2%) were higher as compared to the control experiment in which normal plasma was added to the same platelets.
These findings indicate that the bleeding tendency, which was more pronounced in family A than in family B, does not predict the risk for arterial thrombosis in MYH9-RD patients. Indeed the normal ETP of the individuals of family A and the results of the plasma exchange experiment indicate that a plasma factor rather than increased availability of platelet phospholipids, due to the larger platelet size determine the peak thrombin and ETP in PRP of MYH9-RD patients. This is further underscored by the observation that the plasma of these patients increased the ETP when added to PRP of normal donors in comparison to the autologous plasma of the platelet donor. These index families suggest that thrombin generation studies could be an interesting tool to assess the risk of thrombosis or bleeding in patients with this rare disorder.
Limitations of the study: One limitation of the study is that TGA was performed on frozen samples. The freeze-thaw cycle will cause platelet lysis and any functional aspect of platelets in thrombin generation have not been evaluated. The other major limitation is of course the small size of the study, including only two families. We therefore, suggest that other centers also assess the ETP in their MYH9-RD patients according to our protocol (www.med.lu.se/klinvetmalmo/koagulationsforskning/forskningsprojekt) to gather data on the potential association of the ETP with the phenotype. Table I The endogenous thrombin potential was measured by thrombin generation assay in frozen/thawed "PRP". ETP was seen to be below the normal range in the family not affected by thrombosis (family 2) as expected considering the low platelet counts. In the two family members affected by thrombosis (marked by a star) ETP was normal
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